REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. FIFTH AMENDMENT TO SPONSORED RESEARCH...Sponsored Research Agreement • April 25th, 2023 • CureVac N.V. • Pharmaceutical preparations
This fifth amendment to Agreement (the “Fifth Amendment”), is effective as of January 1, 2023 (“Fifth Amendment Effective Date”), by and between The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having a principal place of business at 20 Staniford Street, Boston, Massachusetts 02114 (“SERI”), and Massachusetts Eye and Ear Infirmary, having a principal place of business at 243 Charles Street, Boston, Massachusetts 02114 (“MEEI”) (collectively, SERI and MEEI shall be referred to herein as “Hospitals”), and CureVac SE, a European Company, having a principal place of business at Friedrich-Miescher-Straβe 15, 72076 Tübingen, Germany (“Sponsor”), each herein referred to as a “Party” and collectively as the “Parties”. Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Agreement (as defined below).
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. FOURTH AMENDMENT TO SPONSORED RESEARCH...Sponsored Research Agreement • April 25th, 2023 • CureVac N.V. • Pharmaceutical preparations
This fourth amendment to Agreement (the “Fourth Amendment”), is effective as of August 31, 2022 (“Fourth Amendment Effective Date”), by and between The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having a principal place of business at 20 Staniford Street, Boston, Massachusetts 02114 (“SERI”), and Massachusetts Eye and Ear Infirmary, having a principal place of business at 243 Charles Street, Boston, Massachusetts 02114 (“MEEI”) (collectively, SERI and MEEI shall be referred to herein as “Hospitals”), and CureVac AG, a German stock corporation, having a principal place of business at Friedrich-Miescher-Straβe 15, 72076 Tübingen, Germany (“Sponsor”), each herein referred to as a “Party” and collectively as the “Parties”. Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Agreement (as defined below).
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential.Covid Cla Fourth Amendment • April 25th, 2023 • CureVac N.V. • Pharmaceutical preparations
Section Page 1. Interpretation 3 2. Effective Date 3 3. Amendment 4 4. Representations and Warranties 4 5. General Provisions 4 Schedule 1. Exhibit 4.1 7
REDACTEDResearch and Option Agreement • April 25th, 2023 • CureVac N.V. • Pharmaceutical preparations
This Research and Option Agreement (this "Agreement") is made and entered into effective as of 12 May 2022 (the "Effective Date") by and between CureVac AG, Friedrich-Miescher-Str. 15, 72076 Tübingen, Germany ("CureVac"), and myNEO NV, Ottergemsesteenweg Zuid 808 box 511, 9000 Ghent, Belgium ("myNEO"). CureVac and myNEO are sometimes referred to herein individually as a "Party" and collectively as the "Parties."
